NCT05781698View on ClinicalTrials.gov

Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

October 20, 2024

Study Completion Date

December 20, 2024

Conditions

Inflammatory Bowel Diseases

Interventions

DRUG

Mesalamine

mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis

DRUG

Fenofibrate

Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia

Trial Locations (1)

32511

Faculty of Medicine, Menoufia University, Tanta

All Listed Sponsors

collaborator

Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University

UNKNOWN

lead

Tanta University

OTHER

NCT05781698 - Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis | Biotech Hunter | Biotech Hunter